RT Journal Article
SR Electronic
T1 Molecular Programs of Glomerular Hyperfiltration in Early Diabetic Kidney Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263340
DO 10.1101/2021.09.13.21263340
A1 Stefansson, Vidar T. N.
A1 Nair, Viji
A1 Melsom, Toralf
A1 Looker, Helen C.
A1 Mariani, Laura H.
A1 Fermin, Damian
A1 Eichinger, Felix
A1 Menon, Rajasree
A1 Subramanian, Lalita
A1 Harder, Jennifer L.
A1 Hodgin, Jeffrey B.
A1 Nelson, Peter J.
A1 Eriksen, Bjørn O.
A1 Nelson, Robert G.
A1 Kretzler, Matthias
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263340.abstract
AB Hyperfiltration (HF) is a state of high glomerular filtration rate (GFR) observed in early diabetes that damages glomeruli, resulting in an iterative process of increasing filtration load on fewer and fewer remaining functional glomeruli. To delineate underlying cellular mechanisms of damage induced by HF, transcriptional profiles of kidney biopsies from Pima Indians with type 2 diabetes with or without early-stage diabetic kidney disease (DKD) were grouped into two HF categories based on annual iothalamate GFR measurements. Twenty-six participants with a peak GFR measurement within two years of biopsy were categorized as the “HF group”, and 26 in whom biopsy preceded peak GFR by >2 years were considered “pre-HF”. The HF group had higher hemoglobin A1c, higher urine albumin-to-creatinine ratio, increased glomerular basement membrane width and lower podocyte density compared to the pre-HF group. A glomerular 1240-gene transcriptional signature identified in the HF group was enriched for endothelial stress response signaling genes, including from endothelin-1, tec-kinase and TGF-β1 pathways, with the majority of the transcripts mapped to endothelial and inflammatory cell clusters in kidney single cell transcriptional data. This analysis reveals molecular pathomechanisms contributing to development of HF and early DKD and involving putative ligand-receptor pairs and downstream intracellular targets linked to cellular crosstalk between endothelial and mesangial cells.Competing Interest StatementDr. Kretzler reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, Astra-Zeneca, NovoNordisc, Eli Lilly, Gilead, Goldfinch Bio, Merck, Chan Zuckerberg Initiative, Janssen, Boehringer-Ingelheim, Moderna, Chinook, amfAR, Angion, RenalytixAI, Retrophin, European Union Innovative Medicine Initiative and Certa outside the submitted work; In addition, Dr. Kretzler has a patent PCT/EP2014/073413, Biomarkers and methods for progression prediction for chronic kidney disease licensed. Dr. L. H. Mariani has received unrelated research funding from NIH-NIDDK, NephCure Kidney International, NCATS, unrelated consulting fees from Reata Pharmaceuticals, Calliditas Therapeutics, Travere Therapeutics, support from Reata Pharmaceuticals for travel to meetings. Dr. J.B. Hodgin reports unrelated grant funding from NIDDK and was Chair of the Renal Pathology Society Research Committee from 2019-2020.Funding StatementThis work was supported in part by the Intramural Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases (DK069062) to HCL and RGN, the American Diabetes Association (Clinical Science Award 1-08-CR-42) to RGN, and (DK083912, DK082841, DK020572, DK092926) to RGK, by the extramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases R24 DK082841 Integrated Systems Biology Approach to Diabetic Microvascular Complications and P30 DK081943 University of Michigan O'Brien Kidney Translational Core Center to MK, via the Chan Zuckerberg Initiative Human Cell Atlas Kidney Seed Network to MK and by JDRF 5-COE-2019-861-S-B JDRF and M-Diabetes Center of Excellence at the University of Michigan to MK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Each participant signed an informed consent document, and the study was approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to ethical considerations including individual privacy protection concerns, the board stipulated that individual-level genotype and gene expression data from this study cannot be made publicly available.